The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Transcend NHL 001: liso-cel in R/R B-cell NHL
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the results of the Transcend NHL 001 study (NCT02631044). This is a phase I study in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel, an investigational, anti-CD19, defined composition, 4-1BB, CAR T-cell product administered at a target dose of CD4+ and CD8+ CAR T-cells. Dr Maloney talks about the use of this CAR-T product in the outpatient setting, the future perspectives for this agent and patient-reported outcomes. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
